BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants

Phase 1

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Apixaban
Drug: Clarithromycin

First Posted Date: 2016-09-23

Last Posted Date: 2016-11-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT02912234

Locations: 🇺🇸
Ppd Development, Llc, Austin, Texas, United States

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Phase 1

Completed

Conditions: Broad Solid Tumor

Interventions: Drug: BMS-986207
Biological: Nivolumab
Biological: Ipilimumab

First Posted Date: 2016-09-23

Last Posted Date: 2024-04-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 101

Registration Number: NCT02913313

Locations: 🇷🇴
Local Institution - 0015, Florești, Romania
🇺🇸
Local Institution - 0003, New York, New York, United States
🇺🇸
Local Institution - 0010, Salt Lake City, Utah, United States

and more 17 locations

Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy

Completed

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2016-09-22

Last Posted Date: 2024-05-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 868

Registration Number: NCT02910999

Locations: 🇩🇪
Local Institution - 0001, Frankfurt, Germany

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

Phase 3

Completed

Conditions: Melanoma

Interventions: Biological: Nivolumab
Biological: Ipilimumab

First Posted Date: 2016-09-19

Last Posted Date: 2020-12-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 106

Registration Number: NCT02905266

Locations: 🇦🇺
Cabrini Hospital, Malvern, Victoria, Australia
🇫🇷
Hopital Saint Louis, Paris, France
🇪🇸
Local Institution, Sevilla, Spain

and more 8 locations

A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment

Phase 1

Completed

Conditions: ESRD (End-Stage Renal Disease)
Factor XI
Thrombosis
Renal Impairment

Interventions: Drug: BMS-986177

First Posted Date: 2016-09-16

Last Posted Date: 2017-07-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 6

Registration Number: NCT02902679

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Phase 3

Completed

Conditions: Mesothelioma

Interventions: Biological: Nivolumab
Drug: Pemetrexed
Biological: Ipilimumab
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2016-09-14

Last Posted Date: 2024-05-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 605

Registration Number: NCT02899299

Locations: 🇺🇸
Local Institution - 0014, New Haven, Connecticut, United States
🇺🇸
Local Institution - 0013, Detroit, Michigan, United States
🇺🇸
Local Institution - 0004, Rochester, Minnesota, United States

and more 104 locations

Phase 1 Study of Mesothelin-ADC

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: BMS-986148

First Posted Date: 2016-08-31

Last Posted Date: 2020-03-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT02884726

Locations: 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan

Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects

Phase 1

Completed

Conditions: Arthritis

Interventions: Drug: BMS-986142

First Posted Date: 2016-08-26

Last Posted Date: 2016-11-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 9

Registration Number: NCT02880670

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

Phase 3

Completed

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer
Esophageal Adenocarcinoma

Interventions: Drug: Oxaliplatin
Drug: Nivolumab
Drug: Leucovorin
Drug: Ipilimumab
Drug: Capecitabine
Drug: Fluorouracil

First Posted Date: 2016-08-19

Last Posted Date: 2024-07-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2031

Registration Number: NCT02872116

Locations: 🇯🇵
Local Institution - 0122, Minato-ku, Tokyo, Japan
🇬🇷
Local Institution - 0017, Nea Kifissia, Attikí, Greece
🇵🇱
Local Institution - 0016, Lublin, Poland

and more 176 locations

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Phase 4

Completed

Conditions: Lung Cancer

Interventions: Drug: Nivolumab in combination with Ipilimumab

First Posted Date: 2016-08-17

Last Posted Date: 2023-06-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1041

Registration Number: NCT02869789

Locations: 🇺🇸
Local Institution - 0170, Reno, Nevada, United States
🇺🇸
Local Institution - 0142, Livingston, New Jersey, United States
🇺🇸
Local Institution - 0134, Cleveland, Ohio, United States

and more 133 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy